Terns Pharmaceuticals, Inc. (TERN) - Stock Analysis
Last updated: Mar 9, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Exceptional short-term momentum following highly positive Phase 1/2 CARDINAL trial data in refractory CML and a $650 million equity raise; 116% price gain over past month and strong institutional demand; significant dilution and technical overextension increase volatility risk; positioned as a speculative hot idea tethered to ongoing clinical developments and regulatory milestones.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Very strong liquidity ⢠Zero reported revenue ⢠Ongoing cash burn TERN has very strong liquidity and negligible debt but faces zero revenue, sustained operating losses and negative cash flow, signaling solvency today but risky long-term viability.
Price Behavior
Key Price Behavior Insights: ⢠Above SMA21 ⢠Near range high ⢠Higher high pattern Support Level: $40.80â$41.50; secondary $39.20â$39.60 Resistance Level: $42.82 TERN is showing shortâterm bullish momentum, trading above its last month SMA (~$39.94) with a higher high but is near the lastâmonth range high/near $42.82, making the move look stretched and vulnerable to a pullback.
Sentiment & News
Key News Insights: ⢠Large buy-ins ⢠Major stake trim ⢠Positive analyst bias Terns saw heightened institutional activityâlarge buys, a major trim, and a new positionâpaired with generally favorable analyst ratings, signaling active rebalancing and strong market interest rather than a single directional bet.
AI Summary
The lateâ2025 equity raise materially deârisks TERN's survival, turning it into a capitalâbacked execution story where valuation now hinges on upcoming TERNâ701 milestones (pivotal dose selection, EOP2 interaction, and pivotal 2L+ start). Actionable focus: monitor interim safety/efficacy data and the FDA interactionâpositive readouts should drive reârating or partner interest, while enrollment delays, safety signals, or a sudden surge in burn that forces early refinancing would materially compress upside.
Description
Terns Pharmaceuticals is a clinical-stage biopharmaceutical firm developing orally administered small-molecule therapies for non-alcoholic steatohepatitis (NASH) and related metabolic disorders, including obesity. Its pipeline includes a liver-distributed FXR agonist in Phase IIa, a VAP-1 inhibitor in Phase Ib, a THRâβ agonist in Phase I, and an oral small-molecule GLPâ1 program; the company was founded in 2016 and is based in Foster City, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 11 | Dec 18 | TERN | Terns Pharmaceuticals, Inc. | Exceptional short-term momentum following highly positive Phase 1/2 CARDINAL trial data in refractory CML and a $650 million equity raise; 116% price gain over past month and strong institutional demand; significant dilution and technical overextension increase volatility risk; positioned as a speculative hot idea tethered to ongoing clinical developments and regulatory milestones. | Closed | -15.5% |